| N (%) | Non carrier (%) | BRCA1 carrier (%) | BRCA2 carrier (%) | p |
---|---|---|---|---|---|
Family history | |||||
 Yes | 113 (84.3) | 95 (84) | 9 (8) | 9(8) | 0.33 |
 No | 21 (15.7) | 20 (95.2) | 1 (4.8) | 0 (0.00) |  |
Age | |||||
 ≤ 30 | 9 (6.7) | 7 (77.8) | 1 (11.1) | 1(11.1) | 0.433 |
 31–40 | 55 (41) | 45 (81.8) | 7 (12.7) | 3 (5.5) |  |
 41–50 | 33 (24.6) | 29 (87.9) | 2 (6.1) | 2 (6.1) |  |
 ≥ 51 | 37 (27.6) | 34 (91.9) | 0 (0.00) | 3 (8.1) |  |
Tumor site | |||||
 Unilateral BC | 104 (77.6) | 92 (88.5) | 4 (3.8) | 8 (7.7) | 0.029 |
 Bilateral BC | 6 (4.5) | 4 (66.7) | 1 (16.7) | 1 (16.7) |  |
 OC | 22 (16.4) | 18 (81.8) | 4 (18.2) | 0 (0.00) |  |
 OC/BC | 2 (1.5) | 1(50) | 1 (50) | 0 (0.00) |  |
Tumor grade | |||||
 SBR II | 82 (73.2) | 73 (89) | 4 (4.9) | 5 (6.1) | 0.41 |
 SBR III | 30 (26.8) | 24 (80) | 2 (6.7) | 4 (13.3) |  |
T-stage | |||||
 T0–T1 | 11 (8.2) | 9 (81.8) | 2 (18.2) | 0 (0.00) | 0.16 |
 T2 | 63 (47) | 56 (88.9) | 2 (3.2) | 5(7.9) |  |
 T3 | 49 (36.6) | 41 (83.7) | 6 (12.2) | 2 (4.1) |  |
 T4 | 11 (8.2) | 9 (81.8) | 0 (0.00) | 2 (18.2) |  |
N-stage | |||||
 No | 54 (40.3) | 48 (88.9) | 3 (5.6) | 3 (5.6) | 0.69 |
 N1–N2 | 80 (59.7) | 67 (83.8) | 7 (8.8) | 6 (7.5) |  |
M | |||||
 M0 | 120 (89.6) | 105 (87.5) | 7 (5.8) | 8 (6.7) | 0.107 |
 M1 | 14 (10.4) | 10 (71.4) | 3 (21.4) | 1 (7.1) |  |
Triple negative | |||||
 No | 84 (76.4) | 75 (89.3) | 1 (1.2) | 8 (9.5) | 0.008 |
 Yes | 26 (23.6) | 21 (80.8) | 4 (15.4) | 1 (3.8) |  |